|Articles|February 1, 2019
- Pharmaceutical Executive-02-01-2019
- Volume 39
- Issue 2
Pharmaceutical Executive, February 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Q&A: Regulatory Reform in Chinaover 7 years ago
China: A Change in Attitudeover 7 years ago
New Roads to Chinaover 7 years ago
Closing the Pharma and Digital Health Divideover 7 years ago
A Leading Man’s Next Actover 7 years ago
Two Steps Forwardover 7 years ago
Let the Drug Pricing Games Beginover 7 years ago
Mixed Outlook for China Life Sciencesover 7 years ago
CFIUS Reform’s Impact on Biopharmaover 7 years ago
Op-Ed: Opening the Golden DoorAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
2
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
3
What the Peptide Advisory Vote Actually Means: Q&A with James LaValle
4
Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech
5